Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S1470-2045(24)00092-5 | DOI Listing |
Cureus
October 2024
Department of Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Int J Clin Oncol
January 2025
Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.
Support Care Cancer
October 2024
Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD, UK.
Invest New Drugs
December 2024
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
Olanzapine combined with the neurokinin-1 receptor antagonist, palonosetron and dexamethasone is the standard treatment for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). However, the use of olanzapine poses challenges in patients with diabetes mellitus (DM) due to the potential risk of hyperglycemia. ME2136, antipsychotic similar to olanzapine, is associated with a lower risk of hyperglycemia.
View Article and Find Full Text PDFInt J Clin Oncol
November 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!